RGCC Southeast Asia

Home
Hong Kong
Hong Kong
RGCC Southeast Asia

About Research Genetic Cancer Centre
RGCC is a specialist medical genetics company, established in 2004 with headquarters in Switzerland.

We are experts in developing and providing personalised cancer genetics tests for doctors and patients, and testing tumours for sensitivity and resistance to chemotherapy treatment and a range of natural substances. We are actively involved in pharmaceutical research and development. Our facilities are equipped with the most technologically advanced equipment and specialised software for data anal

ysis. RGCC is a global organisation, and we work in collaboration with branch offices and distributors to provide a worldwide service.

09/01/2026

At , personalized medicine is at the heart of everything we do.

As Dr. Ioannis Papasotiriou, our Founder and Director, says:
”Every human is not identical. Why should their be identical? Why should every person be treated in the same manner?“

This philosophy drives our dedication to tailor treatments that are as unique as each individual we serve.

31/12/2025

As 2025 comes to a close, we extend our heartfelt gratitude to our partners, clinicians, and patients around the world. May your holidays be filled with peace, health, and hope for the year ahead. ✨ Happy Holidays from all of us at RGCC.

19/12/2025

🎉 Reflecting on a remarkable 2025 at RGCC!

As 2025 draws to a close, we take a moment to reflect on a year marked by scientific progress, collaboration, and continued commitment to advancing personalized oncology.

This year, strengthened its global presence through international gatherings, scientific conferences, and collaborative research initiatives that united leading oncologists, healthcare practitioners, and researchers from around the world. We also celebrated important milestones, including the launch of the InVyomma Plus test.

As we look ahead to 2026, we remain dedicated to expanding the frontiers of precision medicine and supporting clinicians in providing truly personalized cancer care.

09/12/2025

Our Oncotrace test is a powerful monitoring tool designed to assess progression. Through a simple blood draw, Oncotrace detects and analyzes circulating cells (CTCs), evaluating their presence, enumeration, and immunophenotype. This information helps determine how advanced the cancer is and the potential for metastatic spread.

By tracking CTC dynamics over time, Oncotrace enables physicians to monitor disease progression, evaluate treatment effectiveness, and make informed decisions about therapeutic strategies.

14/11/2025

The biology of a cancerous tumor works similarly to skin or hair. Just like the body sheds hair and skin cells, the tumor sheds cells throughout its lifespan. These cells are called circulating tumor cells (CTCs), and they can be detected in the bloodstream. Therefore, when a blood sample is analyzed for diagnosis, the test will measure the presence of CTCs.

At , we use liquid biopsies to measure the CTC count. A liquid biopsy is a non-invasive way to measure cancer in the body by measuring the number of CTCs in the bloodstream.

The detection and monitoring of markers circulating in the blood are useful for the prognosis and prediction of a patient’s response to therapy.

24/10/2025

At , we support healthcare professionals in delivering precision through every stage of the patient journey — from early detection to long-term monitoring.

Empower your clinical decisions with RGCC’s suite of advanced tests >>https://rgccsea.com

15/10/2025

While testicular cancer is rare—affecting about 1 in 250 males—early detection is key. According to the , recent research is uncovering genetic links, such as PLAP, NANOG, SOX2, and REX1, that could help identify those at higher risk in the future.

30/09/2025

Our scientists use world-leading technology, equipment, and innovative techniques to develop a range of screening and monitoring tests. Our tests help cancer patients and their healthcare professionals get a comprehensive but personalized view of each patient’s genetics, physiology, and immune profiles.
We believe this level of detail is crucial in developing an individualized care plan for every struggling with cancer.
-

23/09/2025

🎗️September is Thyroid Cancer Awareness Month 🎗️

Did you know?
Thyroid is often diagnosed at a younger age than many other cancers. It is also more common in women than in men.

The two most common types, Papillary Carcinoma and Follicular Carcinoma, are usually very treatable, especially when detected early.

-

19/09/2025

🌍 RGCC Signs Letter of Intent with Universitas Hasanuddin and PT Wapindo Jasaartha

In May 2025, RGCC International signed a Letter of Intent (LoI) with Universitas Hasanuddin (Indonesia) and PT Wapindo Jasaartha (Klinik Simas Sehat), marking the beginning of a collaborative academic partnership.

This partnership reflects a shared commitment to fostering international academic collaboration and enabling knowledge exchange across institutions in regards to advanced cancer diagnostic technologies.

17/09/2025

Liquid biopsies are transforming diagnostics. By analyzing blood samples for key biomarkers, liquid biopsies offer valuable insights without the need for invasive procedures.

🎥 Hear from Dr. Ioannis Papasotiriou, Founder and Director of , as he explains the critical role of liquid biopsies in early detection and precision oncology: bit.ly/youtubeRGCC

08/09/2025

Our focus is on empowering doctors and patients with personalized insights.
At , our advanced blood tests are designed to detect, analyze, and monitor cancer cells at every stage, helping guide treatment with greater precision.

Address

RGCC Global Ltd, Suite 1701-02, 17/F, FWD Financial Centre, 308 Des Voeux Road Central
Hong Kong

Website

https://rgccsea.com/

Alerts

Be the first to know and let us send you an email when RGCC Southeast Asia posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your business to be the top-listed Engineering Company in Hong Kong?